Cardinal Health (CAH)
(Delayed Data from NYSE)
$113.28 USD
+0.11 (0.10%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $113.27 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.28 USD
+0.11 (0.10%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $113.27 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
Staar Surgical (STAA) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 68% and 1.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Invacare (IVC) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Invacare (IVC) delivered earnings and revenue surprises of -20.45% and 11.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health (CAH) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal fourth-quarter results are likely to reflect solid performance in the Pharmaceutical segment. However, inflation and supply chain constraints are likely to have continued.
Cardinal Health (CAH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardinal Health's (CAH) New Buyout to Boost Medication Adherence
by Zacks Equity Research
Cardinal Health's (CAH) latest acquisition is expected to significantly improve patients' health outcomes with improved medication adherence and increased satisfaction.
New Strong Sell Stocks for July 8th
by Zacks Equity Research
ACER, CAH, and DRI have been added to the Zacks Rank #5 (Strong Sell) List on July 8, 2022.
Cardinal Health (CAH) Buys Bendcare CPO-GPO, Invests in Its MSO
by Zacks Equity Research
Cardinal Health's (CAH) latest acquisition is expected to significantly boost its distribution opportunities and improve patient service.
Cardinal Health (CAH) Ties Up to Deliver Products Via Drones
by Zacks Equity Research
Cardinal Health's (CAH) latest collaboration is expected to significantly boost its distribution strategy and improve patient service.
New Strong Sell Stocks for June 27th
by Zacks Equity Research
CNMD, WMT, and CAH have been added to the Zacks Rank #5 (Strong Sell) List on June 27, 2022.
Should Invesco S&P Ultra Dividend Revenue ETF (RDIV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RDIV
Cardinal Health (CAH) to Extend Warehouse Footing With New Center
by Zacks Equity Research
Cardinal Health's (CAH) new distribution center to support the company's at-Home Solutions business.
Cardinal Health (CAH) Q3 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter results benefit from a solid performance in the Pharmaceutical segment.
Cardinal Health (CAH) Q3 Earnings Miss Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of -5.84% and 4.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Stocks' Earnings May 5 Roster: MCK, CAH & PODD
by Debanjana Dey
The Medical Product companies' quarterly results are likely to reflect base business recovery. Let's see how MCK, CAH and PODD are poised ahead of their earnings releases.
AmerisourceBergen (ABC) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AmerisourceBergen (ABC) delivered earnings and revenue surprises of 7.69% and 0.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health (CAH) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter results are likely to reflect solid performance in the Pharmaceutical segment.
Cardinal Health (CAH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardinal Health (CAH) Stock Moves -1%: What You Should Know
by Zacks Equity Research
Cardinal Health (CAH) closed at $60.63 in the latest trading session, marking a -1% move from the prior day.
Should Invesco S&P Ultra Dividend Revenue ETF (RDIV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RDIV
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, contraction in gross margin is a woe.
Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.
Cardinal Health (CAH) to Extend Medical Distribution Presence
by Zacks Equity Research
Cardinal Health's (CAH) plans to build a new facility in Columbus, OH, can expand its medical distribution footprint in the region.
Zacks Industry Outlook Highlights McKesson, West Pharmaceutical Services and Cardinal Health
by Zacks Equity Research
McKesson, West Pharmaceutical Services and Cardinal Health have been highlighted in this Industry Outlook article.
3 Lucrative Stocks From the Promising Dental Supplies Industry
by Trina Mukherjee
Despite the COVID-19 pandemic-induced challenges, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.
Cardinal Health (CAH) Unveils the First Surgical Incise Drape
by Zacks Equity Research
Cardinal Health's (CAH) introduction of the first surgical incise drape is likely to lower SSIs.